Finasteride and depression: the high cost of failed regulation

Clicks: 5
ID: 332422
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #136 of 136 articles by views in turkish journal of public health

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 136 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract This essay examines the costs of regulatory failure by highlighting the serious neuropsychiatric risks associated with finasteride, a popular hair-loss medication that can cause long-lasting depression and suicidal thoughts. In the United States, illustrative estimates suggest that hundreds of thousands of users may experience depression, over a thousand may die by suicide, and the associated societal costs may approach several billion dollars annually. The article criticizes the FDA and the pharmaceutical industry for failing to conduct or require thorough post-marketing safety studies despite early warning signs. The author concludes that public health must take precedence over corporate interests and shareholder duties. To prevent future similar events, the article proposes regulatory reform that mandates ongoing surveillance. Regulators must require manufacturers to commit to continuous safety monitoring and formal studies after a medication is approved. Regulators must enforce these post-approval study requirements with clear timelines, rather than relying on industry self-discipline, to rebuild public trust and protect citizens from drug safety failures.
Reference Key
openalex_W7222022311 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mayer Brezis
Journal turkish journal of public health
Year 2026
DOI
10.1093/pubmed/fdag077
URL
https://doi.org/10.1093/pubmed/fdag077
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.